Vanguard reports 5.25% stake in CONMED (1.62M shares)
CONMED Corp reports beneficial ownership of 1,619,070 shares as of 03/31/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CONMED Corp reports beneficial ownership of 1,619,070 shares as of 03/31/2026. Vanguard Capital Management states it has sole dispositive power over 1,619,070 shares and sole voting power over 235,028 shares, representing 5.25% of the class. The filing names affiliated Vanguard entities that exercise dispositive or voting power on certain managed accounts.
Insights
Vanguard holds a >5% position in CONMED, reporting dispositive control across managed accounts.
The Schedule 13G filing lists 1,619,070 shares and a 5.25% ownership stake as of 03/31/2026. The report attributes voting and dispositive authority to Vanguard Capital Management and named affiliates across pooled and managed vehicles.
Ownership is presented as aggregated across affiliated investment teams; future changes would appear in updated ownership filings if thresholds shift or voting/dispositive arrangements change.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned financial
Sole dispositive power financial
CUSIP regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What voting and dispositive powers does Vanguard report for CNMD?
Which Vanguard entities are referenced in the CONMED Schedule 13G?
As of what date is the CNMD ownership reported?
Does the filing identify any other person with >5% interest in CONMED?
AI-generated analysis. How Rhea-AI works. Not financial advice.